Healthcare
Erasca, Inc.(ERAS)
Live Price
Offline$13.67
-2.22% today
1Y Change
+990.58%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $3.10B
- Revenue Growth
- 0.0%
- EPS Growth
- +36.2%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Erasca, Inc. (ERAS) is a Healthcare stock with a market cap of $3.10B and listed on NASDAQ. The stock last traded around $13.67 and up 990.6% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +36.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +36.2%, free cash flow +27.6% with operating margin 0.0% and ROIC -37.8%. Stock Foundry combines ERAS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +36.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.8% | -0.6% | +28.8% |
2026 Mar 12, 2026 | +9.1% | -7.0% | +4.2% | +16.1% |
2025 Nov 12, 2025 | +0.0% | -4.2% | +4.2% | +27.5% |
Benchmark Edge
ERAS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ERAS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ERAS Max Drawdown
-59.46%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ERAS and SPY.
Company Overview
Erasca, Inc.
NASDAQ Global Select
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
- Leadership
- Jonathan E. Lim
- IPO Date
- Jul 16, 2021
- Employees
- 103
- Street Address
- 10835 Road to the Cure
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 465 6511
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 8.7
Growth
- Revenue
- 0.0%
- EPS
- +36.2%
- Free Cash Flow
- +27.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -34.5%
- ROIC
- -37.8%
Balance Sheet
- Debt/Equity
- 0.14
- Current Ratio
- 10.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.